METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH)
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug BI 770371 tested for MASH-Related liver scarring
Disease control CompletedThis study tested the safety of a new medicine called BI 770371 in 28 adults with liver cirrhosis caused by MASH (a type of fatty liver disease). Participants received either the drug or a placebo as an IV infusion every 3 weeks for 12 weeks. The main goal was to see if the drug …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH)
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 26, 2026 05:44 UTC
-
MASH awareness survey completed – no treatment involved
Knowledge-focused CompletedThis study used online questionnaires to learn how much healthcare providers and people with or at risk for MASH know about the disease and its links to heart, kidney, and metabolic conditions. Over 1,300 participants completed the survey, which took about 25 minutes. No treatmen…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS(MASH)
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated May 26, 2026 05:59 UTC